BUZZ-ImmunityBio says bladder cancer therapy on track for filing, shares rise
Reuters03-26
BUZZ-ImmunityBio says bladder cancer therapy on track for filing, shares rise
** Shares of drug developer ImmunityBio IBRX.O rise 2.11% to $8.24
** Co says trial for its first-line non-muscle invasive bladder cancer treatment remains on track for final analysis and a supplemental U.S. marketing application in late 2026
** Co says an independent monitoring committee found the late-stage trial had enough patients to test whether its cancer therapy, Anktiva, improves results when added to BCG, a standard bladder cancer treatment
** Review was based on an interim look at 183 patients, or about half of those enrolled, who could be assessed for the main study goal - IBRX
** IBRX shares were down over 22% in 2025
(Reporting by Kunal Das in Bengaluru)
((Kunal.Das2@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments